Brokerages expect Fate Therapeutics Inc (NASDAQ:FATE) to post sales of $1.02 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Fate Therapeutics’ earnings. The lowest sales estimate is $1.00 million and the highest is $1.03 million. Fate Therapeutics reported sales of $1.03 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 1%. The firm is expected to report its next quarterly earnings results on Thursday, March 15th.

According to Zacks, analysts expect that Fate Therapeutics will report full year sales of $1.02 million for the current fiscal year, with estimates ranging from $4.00 million to $4.11 million. For the next year, analysts forecast that the business will report sales of $5.66 million per share, with estimates ranging from $4.02 million to $12.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The company’s quarterly revenue was up .0% on a year-over-year basis.

A number of analysts have issued reports on FATE shares. Raymond James Financial reiterated a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, December 12th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Wednesday, December 13th. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Tuesday. ValuEngine downgraded shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Piper Jaffray Companies initiated coverage on shares of Fate Therapeutics in a report on Monday, December 18th. They issued an “overweight” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $7.64.

In related news, General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.85, for a total transaction of $31,150.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of Fate Therapeutics stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.87, for a total transaction of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in FATE. State Street Corp purchased a new position in shares of Fate Therapeutics during the 2nd quarter worth about $1,437,000. Northern Trust Corp boosted its stake in shares of Fate Therapeutics by 968.7% during the 2nd quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock worth $1,193,000 after purchasing an additional 333,753 shares during the period. TIAA CREF Investment Management LLC purchased a new position in shares of Fate Therapeutics during the 2nd quarter worth about $373,000. Vanguard Group Inc. boosted its stake in shares of Fate Therapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock worth $4,096,000 after purchasing an additional 108,602 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Fate Therapeutics by 164.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 157,546 shares of the biopharmaceutical company’s stock worth $511,000 after purchasing an additional 98,036 shares during the period. 49.85% of the stock is owned by hedge funds and other institutional investors.

Shares of Fate Therapeutics (FATE) opened at $6.70 on Thursday. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. The stock has a market cap of $341.58, a price-to-earnings ratio of -7.05 and a beta of 1.52. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $7.25.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/11/analysts-expect-fate-therapeutics-inc-fate-will-post-quarterly-sales-of-1-02-million.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.